Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial” is a research paper published in Clinical and Molecular Hepatology (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA237327
National Institutes of Health
Grant: P50CA217674
National Institutes of Health
Grant: P30CA016672
National Institutes of Health
Grant: 5P50CA217674-04
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
National Institutes of Health
Grant: 5R01CA237327-05
PEA15 IN DEVELOPMENT OF LIVER CANCER AND ITS THERAPEUTIC IMPLICATION
University of Texas MD Anderson Cancer Center
Duncan Family Institute for Cancer Prevention and Risk Assessment
National Cancer Institute
Fields of Study
Keywords